Introduction: Redefining Vascular Therapy Through Gene Editing

The advent of CRISPR-Cas9 technology has fundamentally altered the landscape of genetic medicine, providing researchers with a scalpel-like tool to precisely alter DNA sequences in living organisms. Within the specialized domain of vascular biology, this capability is opening new frontiers. Vascular cells, particularly endothelial cells lining blood vessels and smooth muscle cells in vessel walls, are central to the pathophysiology of cardiovascular disease (CVD), the leading cause of death globally. By enabling targeted modifications at the genomic level, CRISPR offers a pathway not just to manage symptoms but to correct the molecular underpinnings of vascular dysfunction, potentially halting or reversing diseases such as atherosclerosis, hypertension, and restenosis.

Unlike conventional therapies that broadly target cellular pathways, CRISPR allows for the direct manipulation of genes responsible for inflammation, lipid metabolism, cell proliferation, and apoptosis. This review explores how CRISPR is being applied to enhance vascular cell function, the current state of preclinical research, the obstacles that remain, and the transformative potential for future clinical applications.

Understanding CRISPR and Vascular Cells

The Molecular Mechanism of CRISPR-Cas9

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is an adaptive immune system originally discovered in bacteria and archaea. The system uses a guide RNA (gRNA) to direct the Cas9 nuclease to a specific genomic sequence, where it creates a double-strand break. This break is then repaired by the cell’s endogenous machinery via either non-homologous end joining (NHEJ) or homology-directed repair (HDR). NHEJ often results in small insertions or deletions that disrupt gene function, making it ideal for gene knockout. HDR, on the other hand, uses a donor template to introduce precise edits, enabling gene correction or insertion of therapeutic sequences. Recent advances have yielded even more refined tools, such as base editors and prime editors, which bypass the need for double-strand breaks, minimizing off-target effects and improving safety profiles.

Key Vascular Cell Types and Their Roles

Vascular homeostasis depends on the coordinated function of several cell types:

  • Endothelial cells (ECs): Form the inner lining of blood vessels, regulate vascular tone, control permeability, and secrete factors that inhibit thrombosis and inflammation. Endothelial dysfunction is an early event in atherosclerosis.
  • Vascular smooth muscle cells (VSMCs): Situated in the medial layer, VSMCs contract and relax to regulate blood pressure and flow. They can also undergo phenotypic switching, becoming proliferative and synthetic, which contributes to neointimal hyperplasia and plaque instability.
  • Pericytes and adventitial fibroblasts: Support endothelial integrity and contribute to vessel remodeling and fibrosis.

CRISPR-based interventions can be tailored to each cell type, either correcting intrinsic genetic defects or modulating pathways that drive disease. For example, editing endothelial genes to enhance nitric oxide production can improve vasodilation, while targeting VSMC proliferation genes can reduce restenosis after angioplasty.

How CRISPR Enhances Vascular Cell Function

Correcting Genetic Mutations

Many vascular diseases have a clear genetic basis. Familial hypercholesterolemia, caused by mutations in the LDLR gene, leads to severe atherosclerosis. In animal models, CRISPR has been used to restore functional LDL receptor expression in hepatocytes, dramatically lowering circulating LDL cholesterol and reducing plaque burden. Similarly, mutations in PCSK9 that cause hypercholesterolemia can be disrupted by CRISPR, providing a permanent, one-time alternative to daily statin therapy. For vascular cells directly, correction of eNOS mutations (endothelial nitric oxide synthase) can restore NO production, improving vasodilation and reducing oxidative stress.

Modulating Inflammation and Oxidative Stress

Chronic inflammation is a hallmark of vascular disease. CRISPR can be used to knock out pro-inflammatory genes such as IL-1β, ICAM-1, or VCAM-1, reducing leukocyte adhesion to the endothelium. In mouse models of atherosclerosis, endothelial-specific deletion of IL-1β significantly decreased plaque size and macrophage infiltration. Additionally, editing transcription factors like NF-κB or Nrf2 can simultaneously dampen inflammatory signaling and boost antioxidant defenses, thereby protecting ECs from oxidative damage.

Enhancing Angiogenesis and Regeneration

Ischemic diseases such as peripheral artery disease and myocardial infarction are characterized by insufficient blood vessel growth. CRISPR can be harnessed to promote angiogenesis by activating pro-angiogenic genes like VEGF-A, FGF-2, or HIF-1α. For instance, HDR-based insertion of a constitutively active form of HIF-1α into endothelial cells results in sustained upregulation of angiogenic factors, leading to improved capillary density and perfusion in ischemic limbs of mice. Alternatively, knocking out negative regulators such as TSP-1 or VEGFR-1 can enhance the sensitivity of ECs to growth factors.

Suppressing Pathological Remodeling

In vascular injury (e.g., after stent placement), VSMCs hyperproliferate, causing neointimal hyperplasia and restenosis. CRISPR-mediated knockout of genes such as PCNA, Cyclin D1, or PDGFR-β in VSMCs can limit their proliferation without affecting endothelial healing. In rodent models, local delivery of CRISPR constructs targeting these genes during angioplasty reduced neointimal area by over 50%. Furthermore, editing MMP-9 or LOX can stabilize the extracellular matrix, preventing aneurysm formation.

Application in Specific Vascular Diseases

Atherosclerosis

Atherosclerosis is a complex, multifocal disease driven by lipid accumulation, inflammation, and endothelial dysfunction. CRISPR has been deployed in multiple preclinical settings:

  • Lipid metabolism: Hepatic disruption of PCSK9 using lipid nanoparticle–encapsulated CRISPR systems reduced total cholesterol by 70% in non-human primates (Musunuru et al., Nature, 2021).
  • Plaque stabilization: Endothelial knockdown of IL-6 reduced inflammatory cytokine secretion and promoted fibrous cap integrity.
  • Reverse cholesterol transport: Overexpression of ABCA1 in macrophages via CRISPR activation (CRISPRa) enhanced cholesterol efflux and reduced foam cell formation.

These approaches demonstrate that CRISPR can target both the liver (systemic effect) and the vascular wall (local effect) to combat atherosclerosis.

Hypertension

Hypertension is often linked to dysregulation of the renin-angiotensin-aldosterone system (RAAS). CRISPR has been used to disrupt the AGT gene (angiotensinogen) in the liver, causing sustained blood pressure reduction in spontaneously hypertensive rats (SHRs). A single injection of CRISPR targeting AGT lowered systolic blood pressure by 20-30 mmHg for over a year, with no apparent off-target effects. This approach offers a potential cure for essential hypertension, although concerns about long-term blood pressure adaptation and electrolyte imbalances remain.

Restenosis and In-Stent Stenosis

Despite advances in drug-eluting stents, in-stent restenosis occurs in 5-10% of patients. Local gene editing of VSMCs during balloon angioplasty or stent deployment is a promising strategy. In porcine models, coating stents with CRISPR-laden nanoparticles targeting PLK1 (a cell cycle regulator) reduced neointimal formation by 60% compared to bare-metal stents. Combining CRISPR with biodegradable polymer coatings could provide a “one-and-done” solution for restenosis prevention.

Peripheral Artery Disease and Diabetic Wounds

CRISPR-based pro-angiogenic therapy is particularly compelling for peripheral artery disease (PAD) and chronic wounds. In diabetic mice, topical application of CRISPRa constructs activating VEGF-A in dermal endothelial cells accelerated wound closure by 40% and increased capillary density. Similarly, intramuscular injection of CRISPR-edited endothelial progenitor cells (EPCs) overexpressing SDF-1 improved blood flow in ischemic hindlimb models.

Aortic Aneurysm

Aortic aneurysms involve progressive degradation of the vessel wall by matrix metalloproteinases (MMPs). CRISPR-mediated knockout of MMP-9 in macrophages, combined with upregulation of tissue inhibitors of metalloproteinases (TIMPs), prevented aneurysm expansion in Marfan syndrome mouse models. This dual-editing strategy illustrates the power of multiplex CRISPR to simultaneously address multiple pathological pathways.

Challenges and Ethical Considerations

Delivery Efficiency and Specificity

One of the greatest hurdles for vascular CRISPR therapy is delivering the editing machinery specifically to target cells. Systemic intravenous delivery often results in hepatic accumulation, which is beneficial for liver-targeted therapies (e.g., PCSK9 editing) but inefficient for vascular cells. Local delivery methods are being developed, including:

  • Nanoparticle carriers: Lipid or polymer nanoparticles encapsulating CRISPR components can be functionalized with vascular-targeting ligands (e.g., anti-PECAM-1 antibodies).
  • Adeno-associated virus (AAV) vectors: AAV serotypes such as AAV9 and AAVrh10 show tropism for endothelial and smooth muscle cells, but their small packaging capacity limits delivery of large Cas9 proteins. Smaller Cas variants like Staphylococcus aureus Cas9 or Cas12a can circumvent this.
  • Extracellular vesicles (EVs): EVs derived from endothelial cells can naturally home to damaged vasculature and deliver CRISPR ribonucleoprotein complexes.

Despite these advances, achieving high editing efficiency in the vascular wall without systemic off-target effects remains challenging.

Off-Target Effects and Genotoxicity

Even with improved guide RNA design algorithms and high-fidelity Cas9 variants (e.g., SpCas9-HF1, eSpCas9), unintended edits at similar genomic sites can occur. These off-target events may disrupt tumor suppressor genes or cause chromosomal rearrangements, raising the risk of malignancy. In 2022, a study reported the first case of an off-target deletion leading to a large chromosomal loss in a mouse liver model (Latham et al., Science Advances). Advancing to base editors and prime editors, which do not create double-strand breaks, significantly reduces but does not eliminate off-target errors. Rigorous preclinical validation in human cell lines and animal models is essential before clinical translation.

Immune Responses to CRISPR Components

Cas9 proteins derived from bacterial species (e.g., Streptococcus pyogenes Cas9) can trigger pre-existing humoral and cellular immune responses in humans. A 2023 study found that 65% of healthy adults had antibodies against SpCas9. These immune reactions can neutralize the therapy or cause inflammatory side effects. Strategies to mitigate this include using humanized Cas9 variants, transient immunosuppression, or delivering mRNA rather than DNA to reduce immunogenicity. Enveloped delivery systems that shield the cargo from immune detection are also under investigation.

Ethical Dimensions: Germline Editing and Equity

While current vascular CRISPR applications focus on somatic cells (edits are not heritable), the specter of germline editing looms. Any unintentional editing of germ cells could be inherited, raising profound ethical questions about consent and unintended consequences for future generations. Regulatory bodies such as the FDA and EMA have maintained a moratorium on human germline editing. Additionally, the high cost of CRISPR therapeutics threatens to widen health disparities. Ensuring equitable access through tiered pricing, generic licensing, and public-sector investment will be critical for real-world impact.

Future Directions

Precision Editing Technologies

The field is rapidly moving beyond traditional double-strand break repair. Base editing (developed by David Liu’s group) allows for direct conversion of one base to another without a DNA cut, enabling correction of point mutations (e.g., in eNOS or LDLR). Prime editing offers even greater flexibility by using a Cas9 nickase fused to a reverse transcriptase, capable of inserting, deleting, or swapping any small DNA sequence with high precision. These tools dramatically reduce off-target effects and avoid p53-mediated DNA damage responses, making them safer for therapeutic use.

In Vivo Delivery Innovations

Next-generation delivery systems aim to combine cell specificity with high efficiency. Virus-like particles (VLPs) that package CRISPR ribonucleoproteins without viral genomes offer a hybrid approach: they retain the cell-targeting ability of AAVs but eliminate the risk of viral integration. Lipid nanoparticles (LNPs) optimized for endothelial uptake, such as those with PEGylated surfaces and pH-responsive lipids, have shown up to 40% editing in cardiac endothelium after intravenous injection in mice. The development of “universal” LNPs that can be redirected by surface antibodies (antibody-LNP conjugates) will further improve precision.

Combination Therapies

CRISPR will likely not act alone but be combined with other modalities for synergistic effects. For example:

  • CRISPR editing of PCSK9 + statin therapy could achieve ultra-low LDL levels.
  • CRISPRa of VEGF-A + cell therapy (endothelial progenitor cells) could enhance vascular repair.
  • CRISPR knockout of PD-L1 in tumor vasculature could potentiate immunotherapy.

These combinatorial strategies will require careful timing and dosing to avoid adverse interactions.

Clinical Trials on the Horizon

As of 2025, a handful of CRISPR therapies for cardiovascular indications have entered early-phase clinical trials. Notably, VERVE-101 (Verve Therapeutics) – a base editor targeting PCSK9 in the liver – is in Phase 1b for heterozygous familial hypercholesterolemia. A separate trial involving direct arterial delivery of lentiviral vectors encoding a CRISPR system to inhibit restenosis is enrolling patients in Europe. These initial forays will provide crucial safety and proof-of-concept data. Success could unlock a wave of investment into vascular gene editing.

Personalized Medicine and Disease Modeling

CRISPR is also revolutionizing the study of vascular disease. Patient-derived induced pluripotent stem cells (iPSCs) can be CRISPR-edited to model genetic variants of unknown significance, enabling functional validation of risk loci identified by genome-wide association studies. Furthermore, patient-specific vascular organoids (blood vessel organoids) can be used to screen drug responses and tailor gene editing strategies to individual genotypes. This translational pipeline from bench to bedside promises to accelerate the development of targeted, personalized vascular therapies.

Conclusion

CRISPR technology stands at the threshold of transforming vascular medicine. By directly correcting genetic drivers of disease, modulating inflammatory and regenerative pathways, and enabling local or systemic delivery to the vasculature, gene editing offers possibilities that were unthinkable a decade ago. While challenges in delivery, off-target safety, immunogenicity, and equitable access remain, the pace of innovation is unprecedented. With refined tools such as base and prime editors, improved delivery vectors, and the first clinical trials underway, the era of CRISPR-based therapies for enhancing vascular cell function is no longer a distant prospect but an imminent reality. The next few years will be critical in determining which applications will translate from the lab to the clinic and ultimately improve outcomes for the millions of patients suffering from vascular diseases.

External References:

  • Musunuru, K. et al. (2021). In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. Read the study
  • Latham, R. et al. (2022). Large off-target structural changes following CRISPR-Cas9 editing in mouse liver. Science Advances. Read the study
  • Verve Therapeutics. Phase 1b trial of VERVE-101 for heterozygous familial hypercholesterolemia. Clinical trial information